Cargando…
A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies
BACKGROUND: CD19 is a B cell lineage specific surface receptor whose broad expression, from pro-B cells to early plasma cells, makes it an attractive target for the immunotherapy of B cell malignancies. In this study we present the generation of a novel humanized anti-CD19 monoclonal antibody (mAb),...
Autores principales: | Breton, Caroline S, Nahimana, Aimable, Aubry, Dominique, Macoin, Julie, Moretti, Pierre, Bertschinger, Martin, Hou, Samuel, Duchosal, Michel A, Back, Jonathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021825/ https://www.ncbi.nlm.nih.gov/pubmed/24731302 http://dx.doi.org/10.1186/1756-8722-7-33 |
Ejemplares similares
-
Nicotinaldehyde, a Novel Precursor of NAD Biosynthesis, Abrogates the Anti-Cancer Activity of an NAD-Lowering Agent in Leukemia
por: Matsumoto, Saki, et al.
Publicado: (2023) -
Activation of Bone Marrow-Derived Cells Angiotensin (Ang) II Type 1 Receptor by Ang II Promotes Atherosclerotic Plaque Vulnerability
por: Pellegrin, Maxime, et al.
Publicado: (2018) -
Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agent
por: Cloux, Anne-Julie, et al.
Publicado: (2019) -
The TAT-RasGAP(317-326) anti-cancer peptide can kill in a caspase-, apoptosis-, and necroptosis-independent manner
por: Heulot, Mathieu, et al.
Publicado: (2016) -
Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies
por: Biniecka, Paulina, et al.
Publicado: (2023)